126 related articles for article (PubMed ID: 25301744)
1. Utilization patterns for oral oncology medications in a specialty pharmacy cycle management program.
Deutsch S; Koerner P; Miller RT; Craft Z; Fancher K
J Oncol Pharm Pract; 2016 Feb; 22(1):68-75. PubMed ID: 25301744
[TBL] [Abstract][Full Text] [Related]
2. The impacts of a pharmacist-managed outpatient clinic and chemotherapy-directed electronic order sets for monitoring oral chemotherapy.
Battis B; Clifford L; Huq M; Pejoro E; Mambourg S
J Oncol Pharm Pract; 2017 Dec; 23(8):582-590. PubMed ID: 27733666
[TBL] [Abstract][Full Text] [Related]
3. Specialty pharmacy services for patients receiving oral medications for solid tumors.
Stein J; Mann J
Am J Health Syst Pharm; 2016 Jun; 73(11):775-96. PubMed ID: 27126828
[TBL] [Abstract][Full Text] [Related]
4. Estimated Cost and Savings in a Patient Management Program for Oral Oncology Medications: Impact of a Split-Fill Component.
Staskon FC; Kirkham HS; Pfeifer A; Miller RT
J Oncol Pract; 2019 Oct; 15(10):e856-e862. PubMed ID: 31465250
[TBL] [Abstract][Full Text] [Related]
5. Specialty pharmacy for hematologic malignancies.
Fajardo S; Zook F; Dotson E
Am J Health Syst Pharm; 2016 Jun; 73(11):797-809. PubMed ID: 27126835
[TBL] [Abstract][Full Text] [Related]
6. Pharmaceutical care program for onco-hematologic outpatients: safety, efficiency and patient satisfaction.
Ribed A; Romero-Jiménez RM; Escudero-Vilaplana V; Iglesias-Peinado I; Herranz-Alonso A; Codina C; Sanjurjo-Sáez M
Int J Clin Pharm; 2016 Apr; 38(2):280-8. PubMed ID: 26715547
[TBL] [Abstract][Full Text] [Related]
7. Oral chemotherapy program improves adherence and reduces medication wastage and hospital admissions.
Khandelwal N; Duncan I; Ahmed T; Rubinstein E; Pegus C
J Natl Compr Canc Netw; 2012 May; 10(5):618-25. PubMed ID: 22570292
[TBL] [Abstract][Full Text] [Related]
8. Financial impact of integrated specialty pharmacy efforts to avoid oral anticancer medication waste.
Looney B; Crumb J; White S; Jones G; Moore RP; Choi L; Zuckerman AD; Whelchel K
J Manag Care Spec Pharm; 2024 May; 30(5):465-474. PubMed ID: 38701029
[TBL] [Abstract][Full Text] [Related]
9. Impact of an integrated oral chemotherapy program on patient adherence.
Morgan KP; Muluneh B; Deal AM; Amerine LB
J Oncol Pharm Pract; 2018 Jul; 24(5):332-336. PubMed ID: 28379068
[TBL] [Abstract][Full Text] [Related]
10. Impact of a specialty pharmacy case management service on adherence in patients receiving oral antineoplastic agents.
Middendorff G; Elsey R; Lounsbery B; Chadwell R
J Oncol Pharm Pract; 2018 Jul; 24(5):371-378. PubMed ID: 28509613
[TBL] [Abstract][Full Text] [Related]
11. Impact of a formal pharmacist-run oral antineoplastic monitoring program: A pilot study in an adult genitourinary oncology clinic.
Conliffe B; Figg L; Moffett P; Lauterwasser L; Parsons LB
J Oncol Pharm Pract; 2019 Jun; 25(4):777-786. PubMed ID: 29375014
[TBL] [Abstract][Full Text] [Related]
12. Assessing the need for improved strategies and medication-related education to increase adherence for oral anticancer medications in the young adult oncology population.
Divakaruni A; Saylor E; Duffy AP
J Oncol Pharm Pract; 2018 Jul; 24(5):337-342. PubMed ID: 28387636
[TBL] [Abstract][Full Text] [Related]
13. Initial experience with antiarrhythmic medication monitoring by clinical pharmacists in an outpatient setting: a retrospective review.
Snider M; Kalbfleisch S; Carnes CA
Clin Ther; 2009 Jun; 31(6):1209-18. PubMed ID: 19695388
[TBL] [Abstract][Full Text] [Related]
14. Impact of clinical oral chemotherapy program on wastage and hospitalizations.
Khandelwal N; Duncan I; Ahmed T; Rubinstein E; Pegus C
Am J Manag Care; 2011 May; 17(5 Spec No):e169-73. PubMed ID: 21711067
[TBL] [Abstract][Full Text] [Related]
15. Improved Adherence Rates and Clinical Outcomes of an Integrated, Closed-Loop, Pharmacist-Led Oral Chemotherapy Management Program.
Muluneh B; Schneider M; Faso A; Amerine L; Daniels R; Crisp B; Valgus J; Savage S
J Oncol Pract; 2018 Jun; 14(6):e324-e334. PubMed ID: 29799768
[TBL] [Abstract][Full Text] [Related]
16. Impact of a Pharmacist-Led Hypertension Management Program for Oral Chemotherapy in a Specialty Pharmacy Setting.
Wang G; Truong H; Dang R
J Oncol Pharm Pract; 2023 Jan; 29(1):52-59. PubMed ID: 34738845
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the prescribing patterns, adverse effects, and drug interactions of oral chemotherapy agents in an outpatient cancer center.
Solomon JM; Ajewole VB; Schneider AM; Sharma M; Bernicker EH
J Oncol Pharm Pract; 2019 Oct; 25(7):1564-1569. PubMed ID: 30170514
[TBL] [Abstract][Full Text] [Related]
18. Physician-pharmacist collaboration for oral chemotherapy monitoring: Insights from an academic genitourinary oncology practice.
Holle LM; Puri S; Clement JM
J Oncol Pharm Pract; 2016 Jun; 22(3):511-6. PubMed ID: 25900102
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
Grunberg SM; Rolski J; Strausz J; Aziz Z; Lane S; Russo MW; Wissel P; Guckert M; Wright O; Herrstedt J
Lancet Oncol; 2009 Jun; 10(6):549-58. PubMed ID: 19428297
[TBL] [Abstract][Full Text] [Related]
20. Pharmacists' performance of clinical interventions during adherence support medication reviews.
Hatah E; Tordoff J; Duffull SB; Braund R
Res Social Adm Pharm; 2014; 10(1):185-94. PubMed ID: 23688540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
